GeneNews Announces Resignation of Leslie Auld as CFO and Director and Appointment of Warren Whitehead as Chief Accountant.
TORONTO, Sept. 24, 2018 /PRNewswire/ - GeneNews Limited (TSX :GEN ) ("Gene-News" or the "Company") today announced the resignation of Leslie Auld as Chief Financial Officer (CFO) and Director, and the appointment of Warren Whitehead as Chief Accountant. Ms. Auld is leaving to pursue another opportunity.
"The Board of Directors thanks Leslie very much for the many years of stalwart service in helping to build GeneNews," commented James R Howard-Tripp, GeneNews' Chair-man and CEO. " We wish her all success in her new position."
"Warren Whitehead, who is the Chairman of Plantform Corporation and Chair of the Audit Committee of Aptose Biosciences, as well as having held the role of CFO in multiple companies, is joining GeneNews to guide the expanded cross-border team that will manage the financial reporting, as well as financing activities, as GeneNews strengthens its position as the pioneer of early cancer diagnosis" commented Howard-Tripp. "Warren and I have worked together twice before and look forward to doing so again".
Mr Whitehead is a Chartered Professional Accountant (CPA) and a Certified Management Accountant (CMA) who has held several senior financial management positions with pharmaceutical and biotechnology firms. He is the former CFO of ProMis Neuro-sciences Inc (TSX); former CFO of Arius Research Inc (TSX), providing financial guidance and leadership during the acquisition of Arius by Roche in 2008; former CFO of Labopharm Inc (TSX, NASDAQ) where he completed a series of public equity financings including a cross-border NASDAQ offering.
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health out-comes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.